ARTBIO

About ARTBIO

ARTBIO is a company focused on redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building an ecosystem to maximize their potential. Their patient-centric approach is based on a deep understanding of cancer biology and the infrastructure needed to design, manufacture, and distribute therapies effectively.

Products & Services

Alpha Radioligand Therapies (ART):A new class of therapies aimed at effectively killing tumors while sparing healthy tissues, with a focus on high affinity and selectivity. ARTBIO has over 10 pipeline programs, including lead program AB001 in first-in-human studies, and three undisclosed targets (ABA, ABB, ABC) for multiple solid tumors.

Specialties

Alpha Radioligand Therapies (ART) Cancer Treatment Radiopharmaceuticals Isotope Production (AlphaDirectTM) Pb212 Isotope Utilization

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 132000000 MR: - FA: $132 million FAN: 132000000	D: 2025-07-29 FD: 2025-07-29	7 investors
2	RT: Series A T: - FT: Series A	A: 90000000 MR: - FA: $90 million FAN: 90000000	D: 2023-12-07 FD: 2023-12-07	4 investors

Series B Latest

2025-07-29

$132.0M

7 investors (Pro only)

Series A 2023-12-07

$90.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Emanuele Ostuni

Founding CEO

N

Nick Pullen

Chief Scientific Officer

M

Margaret Yu

Chief Medical Officer

P

Philippe Dasse

Chief Technical Officer

A

Amra Demirovic

Chief Human Resources Officer

N

Nicole Hadas

Chief Legal Officer

View 34 more team members with Pro

Unlock Full Team Directory

Recent News

ARTBIO Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised